Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tizanidine
Drug ID BADD_D02230
Description Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury [T574]. It may also be caused by musculoskeletal injury [A177583]. Regardless of the cause, muscle spasticity can be an extremely painful and debilitating condition. Initially approved by the FDA in 1996, tizanidine is an Alpha-2 adrenergic receptor agonist reducing spasticity by the presynaptic inhibition of excitatory neurotransmitters that cause firing of neurons promoting muscle spasm [FDA label].
Indications and Usage For the management of increased muscle tone associated with spasticity
Marketing Status Prescription; Discontinued
ATC Code M03BX02
DrugBank ID DB00697
KEGG ID D08611
MeSH ID C023754
PubChem ID 5487
TTD Drug ID D01MDT
NDC Product Code 50090-0840; 63629-8533; 61919-221; 68084-775; 63187-673; 43063-455; 50090-0813; 63629-7037; 60505-0251; 68788-9497; 67296-1599; 67296-1567; 70771-1335; 63629-3209; 71335-0737; 50090-0841; 16714-172; 55154-7287; 70934-811; 71610-455; 60760-694; 71610-228; 71610-451; 53002-1418; 63187-009; 50090-2078; 71335-1016; 70518-1598; 50090-0811; 57664-502; 71610-167; 71205-311; 60760-719; 71335-1799; 70518-0573; 68788-7782; 63629-1673; 70518-0133; 50090-5767; 68788-7991; 57664-503; 42291-809; 55111-179; 70771-1336; 60505-0252; 70518-1439; 60760-505; 63187-145; 0904-6418; 43353-167; 29300-168; 0615-8360; 68071-3288; 0904-6898; 71335-0424; 63187-493; 68071-5268; 42291-808; 63629-6432; 68788-9514; 72578-096; 68788-7781; 43063-868; 0615-8274; 70934-268; 71610-345; 50090-2208; 71610-162; 68071-4463; 16714-171; 55111-180; 63187-910; 50268-759; 70518-2210; 67296-1192; 35356-662; 29300-169; 68084-645; 70518-3112; 60760-253; 70518-3181; 60760-782; 68788-6365; 67296-1417; 50436-1180; 67877-614; 60760-263; 71335-0003; 72578-097; 63629-2370; 71335-0914; 50268-760; 68788-6444; 67877-613; 63629-2371; 71610-355
Synonyms tizanidine | 5-chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiadiazole | Zanaflex | tizanidine hydrochloride | tizanidine monohydrochloride | DS 103-282 | Sirdalud
Chemical Information
Molecular Formula C9H8ClN5S
CAS Registry Number 51322-75-9
SMILES C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cardiac disorder02.01.01.003--Not Available
Connective tissue disorder15.06.01.006--Not Available
Inflammation08.01.05.0070.000259%Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.0020.000259%Not Available
Ill-defined disorder08.01.03.049--Not Available
Urinary tract obstruction20.08.01.004--
Blood disorder01.05.01.004--Not Available
Psychotic disorder19.03.01.002--
Hepatobiliary disease09.01.08.003--Not Available
Hyperlipidaemia14.08.03.001--
Cystitis noninfective20.03.02.001--
Vulvovaginal mycotic infection21.14.02.004; 11.03.05.004--Not Available
Liver injury12.01.02.003; 09.01.07.022--Not Available
Traumatic liver injury12.01.02.008; 09.01.08.010--Not Available
Nail atrophy23.02.05.010--Not Available
Acute kidney injury20.01.03.016--
Drug-induced liver injury12.03.01.044; 09.01.07.0230.000388%Not Available
Hepatic cancer16.07.02.004; 09.04.02.008--Not Available
Hepatocellular carcinoma16.07.02.005; 09.04.02.010--Not Available
Candida infection11.03.03.021--
Depersonalisation/derealisation disorder19.14.01.004--Not Available
The 9th Page    First    Pre   9    Total 9 Pages